🏛️ Verified NIH Record • Updated 2025-08-13
A Study of ADRX-0706 in Select Advanced Solid Tumors (NCT06036121)
A Phase 1a/b Study of ADRX-0706 in Subjects With Select Advanced Solid Tumors
🔵 Active, Not Recruiting Phase1 💊 Investigational Drug / Biologic Sponsor: Adcentrx Therapeutics
🩺 Plain-English Summary (8th-Grade Level)
The primary purpose of this study is to assess the safety, tolerability, and pharmacokinetics, and to identify the optimal dose of ADRX-0706 in patients with select advanced solid tumors.
Who can join: Review the eligibility criteria below.
Location: USC Norris Comprehensive Cancer Center — Los Angeles, California
Age range: 18 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (21 Sites)
- USC Norris Comprehensive Cancer Center — Los Angeles, California
- UCLA — Los Angeles, California
- Comprehensive Hematology Oncology — St. Petersburg, Florida
- Moffitt Cancer Center — Tampa, Florida
- Karmanos Cancer Institute — Detroit, Michigan
- Henry Ford Cancer — Detroit, Michigan
- START Midwest — Grand Rapids, Michigan
- The Ohio State University Wexner Medical Center — Hilliard, Ohio
- Stephenson Cancer Center — Oklahoma City, Oklahoma
- Sarah Cannon Cancer Network — Nashville, Tennessee
- University of Texas MD Anderson Cancer Center — Houston, Texas
- START San Antonio — San Antonio, Texas
- START Mountain Region — West Valley City, Utah
- Beijing University Third Hospital — Beijing,
- Fujian Cancer Hospital — Fujian,
- Sun Yat-sen University Cancer Center — Guangzhou,
- Hunan Cancer hospital — Hunan,
- Shandong Cancer Hospital — Jinan,
- Shanghai East Hospital — Shanghai,
- Union Hospital, Tongji Medical College, Huazhong University of Science and Technology — Wuhan,
- Wuhan Union Hospital — Wuhan,
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Solid Tumors
- Study of Pembrolizumab Following Surgery in Patients With Microsatellite Instability High (MSI-H) Solid Tumors — Basking Ridge, New Jersey
- Study of the Effect of Rifampicin on the Pharmacokinetics (PK) of Multiple Doses of Cediranib in Patients With Solid Tumours — Edmonton, Alberta
- Study of Anti-CEACAM5 ADC M9140 in Participants With Advanced Solid Tumors (PROCEADE PanTumor) — Santa Monica, California
- A Safety and Efficacy Extension Study of Pertuzumab in Patients With Solid Tumors Previously Enrolled in a Hoffmann-La Roche-Sponsored Pertuzumab Clinical Trial — Porto Alegre, Rio Grande do Sul
- Safety, Tolerability, and Immunogenicity of mRNA-4157 Alone and in Combination in Participants With Solid Tumors — Los Angeles, California
- Flavored, Oral Irinotecan VAL-413 (Orotecan®) Given With Temozolomide for Treatment of Recurrent Pediatric Solid Tumors — Phoenix, Arizona
Explore by condition: All Solid Tumors clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Review the official NIH record below to find the coordinating site.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.